CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Rufinamide

Last Updated: September 20, 2011
Result type: Reports
Project Number: S0252
Product Line: Reimbursement Review

Generic Name: Rufinamide

Brand Name: Banzel

Manufacturer: Eisai Limited

Indications: Lennox-Gastaut syndrome; adjunctive treatment of seizures

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 15, 2012

Recommendation Type: List with clinical criteria and/or conditions